GLP-1 and Menopause: Weight Loss Evidence and Hormone Therapy Effects
GLP-1 drugs still produce strong weight loss after menopause: tirzepatide cut body weight 23% vs 3% placebo in postmenopausal women, and the STEP pool showed a median −16.4% for semaglutide. Hormone therapy is linked to more loss (16% vs 12% at 12 months), but no trial proves it causes the difference.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Yes. GLP-1 drugs still produce large weight losses in perimenopausal and postmenopausal women, roughly matching results seen in premenopausal women and in the full trial populations. In a post hoc analysis of the SURMOUNT trials, postmenopausal women on tirzepatide lost 23% of body weight versus 3% on placebo [4], and a pooled analysis of six STEP trials found a median loss of −16.4% in postmenopausal women on injectable semaglutide 2.4 mg weekly [5].
As for hormone therapy: several studies report that women using menopause hormone therapy lost more weight on these drugs than women not using it — 16% vs 12% at 12 months in one semaglutide cohort [1][7], and about 35% more weight in a tirzepatide cohort [9]. But every one of these analyses was retrospective or post hoc, and the authors explicitly state that causation cannot be claimed [9]. No randomized trial has tested whether adding hormone therapy increases weight loss.
Why does menopause make weight gain more likely?
Up to 70% of women gain weight during the menopause transition, though the typical gain is modest — an estimated 2.1 kg [1][7]. Bigger changes show up in metabolism and body composition. Across the transition, total 24-hour energy expenditure drops by 9%, and energy spent on spontaneous physical activity drops by 30% [1][7].
Body composition shifts as well: fat mass rises, lean mass falls, and fat accumulates around the abdomen [1][7][3]. A 2026 clinical review in Obesity Pillars states these changes are driven primarily by estrogen deficiency and occur independent of chronological age [3].
These shifts matter for health beyond weight. After menopause, the prevalence of type 2 diabetes, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD, formerly called nonalcoholic fatty liver disease), and cardiovascular disease rises [1][7]. Menopause is an independent cardiovascular risk factor, and cardiovascular disease is the leading cause of death in women [1][7].
How much weight did postmenopausal women lose on tirzepatide (Mounjaro, Zepbound)?
A post hoc analysis published in Obesity combined data from SURMOUNT-1, -3 and -4, with women retrospectively categorized as pre-, peri- or postmenopausal and treated with tirzepatide 15 mg or the maximum tolerated dose versus placebo. The authors include Eli Lilly employees [4].
In SURMOUNT-1, tirzepatide beat placebo at every reproductive stage:
| SURMOUNT-1 result | Premenopause | Perimenopause | Postmenopause |
|---|---|---|---|
| Body weight reduction, tirzepatide vs placebo | 26% vs 2% | 23% vs 3% | 23% vs 3% |
| Waist reduction, tirzepatide vs placebo | 22 vs 4 cm | 20 vs 5 cm | 20 vs 4 cm |
The body weight and waist circumference differences were statistically significant at p < 0.001 [4]. Across all three reproductive stage subgroups, 97% to 98% of participants on tirzepatide achieved at least 5% weight loss, versus 29% to 33% on placebo [4]. Among women with a baseline BMI under 35, 30% to 52% of those on tirzepatide across the subgroups reached a waist-to-height ratio of 0.49 or lower, a marker of low central adiposity. Similar results appeared in SURMOUNT-3 and SURMOUNT-4 [4]. One design limitation: menopausal stage was assigned retrospectively, after the fact [4].
What did the semaglutide (Wegovy, Ozempic) trials show by menopausal status?
An analysis presented by Hurtado Andrade MD et al. at ObesityWeek 2025 (The Obesity Society’s 43rd annual meeting, November 4–7, 2025, Atlanta) pooled six STEP trials — STEP 1, 3, 4, 5, 8 and 9 — of injectable semaglutide 2.4 mg weekly for 68 weeks, plus the OASIS 4 trial of oral semaglutide 25 mg daily for 64 weeks [5]. This was a conference slide presentation with Novo Nordisk industry authors, not a peer-reviewed paper.
The STEP pool included 876 premenopausal women (40.7%), 414 perimenopausal (19.2%) and 861 postmenopausal (40.0%) [5]:
| STEP pool, median change | Premenopause | Perimenopause | Postmenopause |
|---|---|---|---|
| Body weight | −18.0% | −17.7% | −16.4% |
| Waist circumference | −16.5 cm | −15.2 cm | −14.0 cm |
The presenters concluded that weight loss was clinically meaningful regardless of menopausal status and consistent with the full trial populations [5]. Adverse events were similar across groups; gastrointestinal disorders occurred in 79.0% of premenopausal, 73.2% of perimenopausal and 71.2% of postmenopausal women in the STEP pool [5].
Does age or menopausal status change how much weight women lose?
Possibly, according to early research. An abstract presented at the ADA Scientific Sessions 2026 (abstract 1711-P, Dermit et al., published in Diabetes 2026;75(Suppl 1)) analyzed STEP 1 (n=1,482) and SELECT (n=17,604), both testing semaglutide 2.4 mg against placebo in adults with overweight or obesity without type 2 diabetes [6].
Prior post hoc analyses indicate women achieve about 40% greater weight loss than men on GLP-1 receptor agonists, and this abstract reports that difference is not fully explained by drug exposure [6]. In SELECT, men showed consistent weight loss from ages 45 to 90, while weight loss in women decreased with age. Circulating FSH and LH — hormones that mark menopausal status — predicted the magnitude of weight loss, particularly during perimenopause (p < 0.05) [6].
This is a conference abstract, not a peer-reviewed full paper, and the analysis involves Novo Nordisk authors [6].
Does hormone therapy increase weight loss on semaglutide?
A retrospective Mayo Clinic Health System cohort study published in Menopause in 2024 — restricted to postmenopausal women treated with semaglutide for overweight or obesity for at least 3 months — compared 16 women on hormone therapy with 90 women not on hormone therapy [1][7]. Hormone therapy consisted of transdermal or oral estradiol, with or without a progestogen, started before semaglutide and continued throughout [1][7]. As part of its data collection, the study recorded each patient’s semaglutide dosing in two categories: low dose (0.25 to 1 mg weekly) and high dose (1.7 to 2.4 mg weekly) [1][7].
| Total body weight loss | On HT (n=16) | No HT (n=90) | P value |
|---|---|---|---|
| 3 months | 7 ± 3% | 5 ± 4% | 0.01 |
| 6 months | 13 ± 6% | 9 ± 5% | 0.01 |
| 9 months | 15 ± 6% | 10 ± 6% | 0.02 |
| 12 months | 16 ± 6% | 12 ± 8% | 0.04 |
The association held after adjustment for confounders, and at 12 months a greater share of hormone therapy users reached at least 5% and at least 10% total body weight loss. Both groups improved cardiometabolic risk markers [1][7].
Important caveats: the groups were not balanced at baseline — White race, dyslipidemia and depression were more prevalent in the no-hormone-therapy group — and the authors call for larger studies to confirm the findings [1][7].
Two supporting signals exist, both with limits. In the STEP pool sensitivity analysis, postmenopausal women categorized as using hormone therapy (n=98) had a median loss of −18.2% versus −16.1% without (n=763), with 46.3% versus 33.3% achieving at least 20% weight loss and waist reductions of −15.9 versus −13.5 cm — but Novo Nordisk notes the hormone therapy category also included systemic contraceptive use, and states the finding requires further investigation [5]. And in the ADA abstract, a STEP 1 subgroup of women over 55 on exogenous estradiol (n=30) lost 20% versus 16% in matched controls (p=0.009) [6].
What about tirzepatide plus hormone therapy?
A retrospective Mayo Clinic-led cohort study published in The Lancet Obstetrics, Gynaecology, & Women’s Health reviewed 120 participants with overweight or obesity who took tirzepatide for weight management for 12 or more months, comparing hormone therapy users with participants of similar characteristics not using it [8][9].
Women using menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone [9]. Senior author Maria Daniela Hurtado Andrade, M.D., Ph.D., stated directly: because this was not a randomized trial, “we cannot say hormone therapy caused additional weight loss” [9]. She noted alternative explanations — hormone therapy users may already have had healthier behaviors, or symptom relief may have improved sleep and made it easier to stay with diet and activity changes [9]. First author Regina Castaneda, M.D., pointed to preclinical data suggesting estrogen may enhance the appetite-suppressing effects of GLP-1 [9].
The study was funded by the Mayo Clinic Center for Women’s Health Research, and the team plans a randomized trial next [9].
Should anyone start hormone therapy just to lose more weight?
No clinical body in these sources supports that. The Obesity Pillars review states that menopause hormone therapy may attenuate central fat accumulation and preserve favorable body composition, but it is not indicated as a primary weight loss intervention [3]. That review lists the established indications for hormone therapy as moderate to severe vasomotor symptoms, osteoporosis prevention, treatment of hypoestrogenism, and treatment of vulvovaginal symptoms — each after an individualized risk-benefit assessment — and states hormone therapy should not be marketed or prescribed for weight loss or obesity treatment [3].
The same review notes that the observational data on combining hormone therapy with obesity medications are limited by small samples, retrospective design and confounding, and require validation in rigorous trials [3]. It frames comprehensive obesity treatment around four pillars: nutrition, physical activity, behavioral modification, and medical intervention, including metabolic/bariatric surgery and FDA-approved obesity medications when indicated [3]. A 2026 expert position statement from the Spanish Menopause Society on incretin-based therapies in peri- and postmenopausal women with obesity also exists in Maturitas [2].
Do these drugs help hot flashes or night sweats?
There is no evidence in these sources that any GLP-1 drug is approved or effective for menopausal symptoms. Hot flashes and night sweats affect up to 75% of postmenopausal women, and hormone therapy is described as the most effective first-line treatment for menopausal symptoms including these [9]. A 2026 review in Cureus examines GLP-1 receptor agonists for obesity and symptoms in menopause, but only its title-level information was verifiable here, so its conclusions cannot be reported [11].
What about muscle and bone during weight loss after menopause?
The menopause transition itself reduces lean mass [1][7][3], which is why muscle gets attention during any weight loss after menopause. Hormone therapy has been associated with attenuating lean mass loss and with a 1% increase in lean mass, and with attenuating the increase in total and visceral abdominal adiposity by around 60%, plus a 0.8% decrease in waist circumference and BMI [1][7].
A 2026 systematic review and meta-analysis in Drugs addresses GLP-1 receptor agonists and musculoskeletal outcomes, but only title-level information was verifiable here, so its effect sizes cannot be reported [12].
What about contraception and oral hormones while on these drugs?
A 2026 Maturitas review describes a biologically plausible but hypothesis-generating pharmacokinetic interaction between tirzepatide and oral progestogens used in gynecologic disease control and menopausal hormone therapy [16]. The specific label guidance on oral contraceptive exposure or switching was not available here, so it cannot be stated. The prescribing information for Zepbound (tirzepatide injection, initial U.S. approval 2022) is available at uspl.lilly.com [13], and Novo Nordisk publishes prescribing information for Ozempic and Wegovy [14][15]. Anyone who could still become pregnant should check the specific product label and raise contraception with a prescriber [13][15].
What should I raise with a clinician?
Reasonable topics include: whether current weight change reflects the menopause transition, aging, or both [1][3]; whether hormone therapy is indicated on its own merits — vasomotor symptoms, osteoporosis prevention, hypoestrogenism, or vulvovaginal symptoms [3]; and nutritional and behavioral support, since dietitian visits and behavior modification were tracked as factors affecting semaglutide response in the Mayo cohort [1][7].
This page describes research findings only. It is not medical advice and does not recommend any medication, dose, or treatment decision. Decisions about GLP-1 drugs, hormone therapy, or contraception belong with a clinician who knows your full history.
Sources
- Menopause. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. April 2024.
- Maturitas. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.
- Obesity Pillars. Clinical review: Menopause hormone therapy in weight management. June 2026.
- PubMed. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.
- Novo Nordisk Science Hub. STEP OASIS WH CM OW25 conference slides on semaglutide and menopausal status.
- Diabetes. 1711-P: Menopausal hormonal status and estradiol use modulate semaglutide-associated weight loss in women: analyses from STEP1 and SELECT. June 2026.
- Menopause. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. April 2024.
- The Lancet Obstetrics, Gynaecology, & Women’s Health. The role of menopause hormone therapy in modulating tirzepatide-associated weight loss in postmenopausal women with overweight or obesity: a retrospective cohort study.
- Mayo Clinic News Network. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. January 22, 2026.
- ClinicalTrials.gov. Clinical study record NCT06715514.
- Cureus. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) for obesity and symptoms in menopause: a review.
- Drugs. GLP-1 receptor agonists and musculoskeletal outcomes: a systematic literature review and meta-analysis. September 12, 2026.
- Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, for subcutaneous use: prescribing information highlights. Initial U.S. approval 2022.
- Novo Nordisk. OZEMPIC (semaglutide) injection, for subcutaneous use: prescribing information. Initial U.S. approval 2017.
- Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use: prescribing information.
- Maturitas. Tirzepatide and oral progestogens: a hypothesis-generating review of a biologically plausible pharmacokinetic interaction in gynaecologic disease control and menopausal hormone therapy.
Frequently asked questions
Do GLP-1 drugs work as well after menopause as before?
Yes, according to the available analyses. In the pooled STEP trials, median weight loss was −18.0% premenopausal, −17.7% perimenopausal and −16.4% postmenopausal on injectable semaglutide 2.4 mg weekly, and the presenters called all three clinically meaningful. Tirzepatide results were similar across stages.
How much weight did postmenopausal women lose in the tirzepatide trials?
In SURMOUNT-1, postmenopausal women on tirzepatide lost 23% of body weight versus 3% on placebo (p < 0.001), with waist reductions of 20 versus 4 cm. Across reproductive stages, 97–98% on tirzepatide achieved at least 5% weight loss versus 29–33% on placebo.
Does estrogen or hormone therapy boost semaglutide weight loss?
It is associated with more loss, but not proven to cause it. In a Mayo cohort of postmenopausal women — 16 on hormone therapy and 90 not on it — 12-month loss was 16% vs 12% (P=0.04), an association that held after adjustment for confounders. The authors call for larger studies.
Is the hormone therapy weight-loss finding proof of cause and effect?
No. All human data are retrospective or post hoc. The tirzepatide study's senior author stated, "Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss". A randomized trial is planned.
Should hormone therapy be started just to lose more weight?
No. The Obesity Pillars review states hormone therapy should not be marketed or prescribed for weight loss or obesity treatment, and lists its established indications as vasomotor symptoms, osteoporosis prevention, hypoestrogenism and vulvovaginal symptoms after individualized risk-benefit assessment.
Why do women lose more weight on semaglutide than men, and does that change with age?
Post hoc analyses indicate women achieve about 40% greater weight loss than men, not fully explained by drug exposure. In SELECT, men's weight loss was consistent from ages 45 to 90, while women's decreased with age; FSH and LH predicted loss magnitude, especially in perimenopause (p<0.05).
Is weight loss harder in perimenopause than postmenopause?
The trial data show only small differences. Median loss in the STEP pool was −17.7% perimenopausal versus −16.4% postmenopausal, and tirzepatide produced 23% vs 3% placebo in both peri- and postmenopausal women in SURMOUNT-1. The ADA abstract suggests perimenopausal hormone levels predict loss magnitude.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.